CDD Awarded $1.5 Million Grant to Automate Open Source Machine Learning ModelsApril 25, 2017-Collaborative Drug Discovery (CDD) proposes to develop technology that will vastly simplify and integrate all the processes required to exploit predictive models for drug discovery. The software will make it easy for scientists without specialized training in informatics to create, train, apply, evaluate, share, and archive models with minimal effort, and also leverage a large library of pre-computed models with zero effort. The software will also enable scientists working in different organizations to collectively build models from their aggregated data and share these models with each other, without sharing the underlying training data.
Our goal is to democratize the role in drug discovery of computational models – which have historically been restricted to computational experts – and allow models to become routine aids to the discovery workflow in academia, foundations, government laboratories, and small companies that do not have the resources to employ them today...
Optibrium and Collaborative Drug Discovery Partner on Integration of StarDrop with CDD VaultOctober 31, 2016-Collaboration provides a comprehensive platform for data management, analysis and compound design in drug discovery CAMBRIDGE, UK and CALIFORNIA, USA, 31 October, 2016 – Optibrium™ and Collaborative Drug Discovery (CDD), developers of software products and services for drug discovery and development, today announced a collaboration to integrate the StarDrop™ and [...]
CDRD Chooses CDD for New Drug Discovery Informatics PlatformFebruary 11, 2016-Press release BURLINGAME, CA and VANCOUVER, BC (February 11, 2016) — Collaborative Drug Discovery (CDD) today announced that The Centre for Drug Research and Development (CDRD) has chosen CDD Vault to replace their Drug Discovery Informatics Platform. After in-depth evaluation of leading systems, CDRD decided on the CDD Vault platform. CDD Vault is a hosted [...]
Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery published in PLOS Neglected Tropical DiseasesJune 26, 2015-We are pleased to announce that the results of a phase I STTR collaborative study on Chagas Disease with groups at SRI International, UCSD, and UCSF have just been published in PLOS Neglected Tropical Diseases.
Chagas disease is a neglected tropical disease caused by the eukaryotic parasite Trypanosoma cruzi. We used a combination of cheminformatics, bioinformatics, in vitro and in vivo testing to identify molecules active at eliminating the parasites from infected cells. We found that the European Medicines Agency approved antimalarial drug pyronaridine possessed 85.2% efficacy (reduction in parasite burden compared to untreated control group after 4 days treatment) in the acute Chagas mouse model and may represent a repurposing opportunity.
This study also utilized the public T. cruzi datasets present in the CDD Vault. “This project demonstrates what can be achieved by combining complimentary approaches...
CDD Awarded $1.5 Million Grant to Simplify Encoding of Bioassays with Automated Annotation TechnologyJune 17, 2015-Burlingame, Calif.—June 17, 2015—Collaborative Drug Discovery, provider of CDD Vault® web-based drug discovery informatics platform, announced they have been awarded a $1.5M Phase 2 SBIR grant to use the Bioassay Ontology Annotator as the foundation for a collaborative CDD ELN (Electronic Laboratory Notebook).
The Bioassay Ontology Annotator software provided a strong proof-of-concept that one could use new automation technologies for comparison of assay conditions
Introducing Eight New Chemical Libraries in CDD VaultJune 24, 2014-BURLINGAME, Calif. and Niagara-on-the-Lake, Canada — June 24, 2014 — Collaborative Drug Discovery (CDD) and Life Chemicals are proud to announce the availability of eight new chemical libraries in the CDD Vault software platform. These collections have over 370,000 original compounds selected for diversity and lead-like or drug-like properties. “We decided to highlight some of the [...]
Collaborative Drug Discovery (CDD) Announces Customer Advisory Board (CAB) MembersMay 27, 2014-BURLINGAME, Calif. — May 27, 2014 — Collaborative Drug Discovery (CDD) is delighted to announce the members of our commercial Customer Advisory Board (CAB). The following industry thought leaders were carefully selected to help guide the short-term and long-term development of the CDD Vault platform:
Jeff Blaney, Director Computational Chemistry & Chemoinformatics (Genentech)
Henry Johnson, Senior Scientist (Amgen, Onyx Pharmaceuticals subsidiary)
Thale Jarvis, VP Research & Development (Crestone Pharmaceuticals)
Mark Gurney, CEO (Tetra Discovery Partners)
Paul Humphries, VP Chemical Sciences (Reset Therapuetics)
Daniel Erlanson, President (Carmot Therapeutics)
As reported at the 10 Year Anniversary CDD User & Community Meeting, CDD Vault has the same number of user logins/month as a full year in 2008.
CDD’s Product Manager, Kellan Gregory, commented...
Cheaper and faster screening for antibacterialsMay 8, 2013-BURLINGAME, Calif. — Scientists have collaborated to develop a way to reproducibly find promising molecules against the bacteria tuberculosis (TB) in silico, using off the shelf software. A team led by Sean Ekins at Collaborative Drug Discovery in Burlingame, CA with co-authors at the University of Medicine and Dentistry of New Jersey, Southern Research Institute, [...]
BIO5 Partners with Collaborative Drug Discovery to Manage Burgeoning Internal Compound CollectionMarch 28, 2013-BIO5 Partners with Collaborative Drug Discovery to Manage Burgeoning Internal Compound Collection TUCSON, Ariz., March 28, 2013 — The University of Arizona’s BIO5 Institute Oro Valley (BIO5-OV) has partnered with Collaborative Drug Discovery (CDD), Inc. to use the CDD Vault, a state-of-the-art cloud technology, to capture and securely share BIO5’s drug discovery research data. [...]
Informatics Considerations at the Dawn of the Antibody Drug Conjugate EraFebruary 25, 2013-Congratulations to Genentech/Roche-ImmunoGen on the FDA Approval of Kadcyla (Ado-Trastuzumab Emtansine), an Antibody-Drug Conjugate for Her2-Positive Metastatic Breast Cancer Antibody-Drug Conjugates (ADCs) combine the best of Nature’s capacity to rapidly evolve specificity with Science’s capacity to deliver specifically designed functionality. There are fascinating, unique ADC SAR (Structure Activity Relationship) informatics representation and optimization challenges when [...]
Michael Siani-Rose Brings Diverse Talents to CDDNovember 27, 2012-Mr. Michael Siani-Rose brings his successful track record at Affymetrix, Chiron, Kosan, and Gryphon to CDD. Michael Siani-Rose (CDD Informatics) was most recently President of Cell Therapy Company Theregen. Of particular relevance for CDD, with the emergence of Antibody Drug Conjugates and informatics standards such as HELM from big pharmas, Michael Siani-Rose co-published with SMILES [...]
Drug Discovery Informatics Veteran Joins CDDNovember 5, 2012-Dr. Michael Travers brings a reproducible track record of commercially successful, informatics innovation to CDD’s strong technical team. Dr. Travers’ broad bioinformatics and chemoinformatics experience adds an eclectic wind to CDD’s sail. Dr. Michael Travers (CDD Software Design) hails from SRI International’s Bioinformatics Research Group, where he worked on developing software tools to support [...]
CDD Welcomes Charlie Weatherall to Scale Accounts ManagementSeptember 28, 2012-Press release BURLINGAME, Calif., 27 Sept 2012 — Collaborative Drug Discovery (CDD) announces the addition of Charlie Weatherall to magnify CDD’s focus on its Community, further promoting the widespread acceptance of CDD’s platform among academic, government, biotech and pharma researchers. Prior to joining CDD, Charlie Weatherall worked with industry-leading scientific software companies such as MDL (dating [...]
National Institute of Allergy and Infectious Diseases Awards Grant to Continue Development of Computational Tools for Tuberculosis Drug DiscoveryAugust 16, 2012-The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded a second grant to Collaborative Drug Discovery, Inc. and SRI International to continue joint development of an information repository and software to identify novel therapeutics for tuberculosis (TB).
The Phase II Small Business Technology Transfer Research (STTR) grant will support the next two years of research and focus on extending a systems biology-cheminformatics approach to develop molecular mimics and computationally evaluate them for drug efficacy.
CDD Provides Technology in Global Consortium to Identify New Tuberculosis DrugsMarch 4, 2011-Burlingame, CA, March 4, 2011 — Collaborative Drug Discovery, Inc. (CDD; https://www.collaborativedrug.com/) has joined the École Polytechnique Fédérale de Lausanne (EPFL), AstraZeneca, Sanofi-Aventis, the Universities of Pavia, Uppsala and Cambridge, and nearly twenty other research groups from 13 different countries, to form the More Medicines for Tuberculosis (MM4TB; http://www.mm4tb.org/) consortium, which aims to develop new [...]
Collaborative Drug Discovery, Inc. & Royal Society of Chemistry’s ChemSpider Announce PartnershipFebruary 25, 2011-BURLINGAME, CA. and Wake Forest, N.C., February 21st, /PRNewswire/ — Collaborative Drug Discovery (CDD), the provider of the most widely used cloud-based drug discovery software platform on the market and Royal Society of Chemistry’s (RSC) ChemSpider, a leading provider of chemical services and data on the internet, have implemented two-way linking of public compounds that [...]